Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsHealthSpring ABRYSVO Prior Auth Coverage | OpenPay…
    Ask Trek AI about this page
    CurrentHealthSpringPolicy N/A

    ABRYSVO RSV Vaccine Prior Authorization Criteria

    Customize your policy alerts

    Sign up for all healthspring policy alerts

    Know when healthspring releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs prior authorization for ABRYSVO (PF) under the HealthSpring Medicare Part D benefit. Coverage applies to non-pregnant individuals meeting specified age or risk criteria and to pregnant individuals at 32 through 36 weeks of gestation, provided they have not already received an RSV vaccine.

    Policy Summary
    PayerHealthSpring
    PolicyABRYSVO RSV Vaccine Prior Authorization Criteria
    Policy CodePolicy N/A
    Change TypeNo material clinical or coverage changes
    Effective DateN/A
    Last ReviewNov 1, 2026
    Next Review DateN/A
    Key ActionSubmit a prior authorization request establishing that the patient meets the applicable age, risk, or gestational-age criteria and has not already received an RSV vaccine.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    3 monthsCoverage duration
    50+Non-pregnant age threshold
    18–49Non-pregnant age range with increased risk
    32–36 weeksPregnancy eligibility

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    No prior RSV vaccine
    Required vaccination history

    Covered Products and Clinical Criteria

    Initial ABRYSVO Through Cerezyme Product Criteria

    Covered when the product-specific indication, age, prescriber, diagnostic, and prior-therapy requirements below are met.

    Product-specific criteria

    • ABRYSVO: Non-pregnant patient is at least 50 years old, or is 18–49 years old and at increased risk for lower respiratory tract disease; alternatively, pregnant patient is 32–36 weeks gestational age. Patient has not previously received an RSV vaccine.
    • AKEEGA: Prostate cancer indication documented and therapy is prescribed for the applicable FDA-approved disease setting.
    • Aldurazyme: Diagnosis of mucopolysaccharidosis type I is confirmed by appropriate enzyme or molecular diagnostic testing.
    • Alecensa: Patient has an appropriate ALK-positive disease-specific indication and treatment is prescribed by or in consultation with an oncology specialist.
    • Alosetron: Severe chronic diarrhea-predominant irritable bowel syndrome in an appropriate patient for the approved indication.
    • Alpha-1 proteinase inhibitor: Documented severe alpha-1 proteinase inhibitor deficiency with the applicable pulmonary disease or emphysema criteria.
    • Alunbrig: Unresectable, locally advanced, or metastatic ALK-positive non-small cell lung cancer, or another applicable FDA-approved disease-specific indication.
    • Alyftrek/ALYFTREK: Patient has cystic fibrosis with a qualifying CFTR mutation and meets the product's age and genotype requirements.
    • Ambrisentan: Pulmonary arterial hypertension confirmed by appropriate clinical and hemodynamic evaluation.
    • ANKTIVA: High-risk BCG-unresponsive non-muscle-invasive bladder cancer with carcinoma in situ; used in combination with BCG. Initial therapy is for patients at least 18 years old and prescribed by or in consultation with an oncologist or urologist.
    • ARANESP: Qualifying anemia associated with chronic renal failure, cancer chemotherapy, or myelodysplastic syndrome; hemoglobin and serum erythropoietin requirements must be met. Dialysis-related anemia is not covered under Part D and should be billed under the ESRD bundled payment benefit.
    • ARCALYST: Initial therapy meets the applicable approved indication and diagnostic requirements; continuation demonstrates clinical response or ongoing medical necessity.
    • AREXVY: Patient meets the product's age and eligibility requirements for RSV vaccination and has not already received an RSV vaccine.
    • ARIKAYCE: Refractory Mycobacterium avium complex lung disease with appropriate microbiologic confirmation and use as part of a multidrug regimen.
    • Armodafinil: Narcolepsy, obstructive sleep apnea/hypopnea syndrome, or shift-work sleep disorder documented for the approved indication.
    • Atypical antipsychotic: Product is prescribed for a covered FDA-approved or medically accepted indication with appropriate clinical documentation.
    • AUGTYRO: Appropriate oncology indication, including a qualifying NTRK fusion-positive solid tumor or ROS1-positive non-small cell lung cancer, is documented.
    • AUSTEDO: Huntington disease-associated chorea or tardive dyskinesia documented, with treatment prescribed for the applicable indication.
    • AYVAKIT: Appropriate disease-specific indication, such as qualifying gastrointestinal stromal tumor, systemic mastocytosis, or another FDA-approved indication, is documented.
    • AVMAPKI-FAKZYNJA: Patient meets the applicable disease and molecular eligibility requirements. Initial therapy requires confirmation of the qualifying mutation or disease-specific indication.
    • BALVERSA: Locally advanced or metastatic urothelial carcinoma with the qualifying FGFR genetic alteration and appropriate prior therapy is documented.
    • BENLYSTA: Active systemic lupus erythematosus or lupus nephritis is documented. Initial and continuation therapy require the applicable concomitant standard therapy and clinical response or ongoing medical necessity.
    • CAMZYOS: Continuation requires documented clinical benefit, ongoing monitoring, and compliance with applicable REMS requirements.
    • Cerezyme: Gaucher disease is confirmed by appropriate enzyme, molecular, or other diagnostic testing.

    ARANESP Through BENLYSTA Criteria

    Coverage requires the applicable diagnosis, laboratory documentation, specialist involvement, and duration requirements.

    Product-specific criteria

    • ARANESP: For anemia of chronic renal failure not on dialysis, hemoglobin is below the applicable initiation threshold; for chemotherapy-associated anemia, the patient is receiving myelosuppressive, non-curative chemotherapy and meets the hemoglobin threshold; for MDS, hemoglobin is at or below 10 g/dL or serum erythropoietin is at or below 500 mU/mL. Deny when hemoglobin exceeds 12 g/dL.
    • BENLYSTA initial therapy: Active systemic lupus erythematosus or lupus nephritis meets the approved indication and the patient is receiving appropriate background therapy.
    • BENLYSTA continuation therapy: Patient has demonstrated clinical response or continued medical necessity and remains on appropriate background therapy.
    • ARANESP operational requirements: MDS therapy is for patients at least 18 years old and is prescribed by or in consultation with a hematologist or oncologist. Coverage duration is generally 6 months for chemotherapy-associated anemia and 1 year for CKD or MDS.

    Bexarotene Through Deferasirox Criteria

    The following products require confirmation of the named disease or approved indication before authorization.

    Disease-specific criteria

    • Bexarotene: Appropriate cutaneous T-cell lymphoma diagnosis is documented; initial and continuation therapy are prescribed by or in consultation with an oncologist or dermatologist.
    • Chemet: Patient is 12 months through 18 years old, has acute lead poisoning rather than prophylactic use, and had a pretreatment blood lead level greater than 45 mcg/dL; prescriber is experienced in chelation therapy.
    • Chorionic gonadotropin: Product is used for a covered, medically necessary hormonal or reproductive indication with supporting diagnostic documentation.
    • Clobazam: Lennox-Gastaut syndrome or another covered indication is documented; continuation requires clinical benefit and tolerability.

    Dimethyl Fumarate Through Other Indication-Based Products

    Coverage is limited to the documented indication and applicable diagnostic, laboratory, and prior-treatment requirements.

    Product-specific criteria

    • Dimethyl fumarate: Relapsing multiple sclerosis or another covered multiple-sclerosis indication is documented.
    • Doptelet: Thrombocytopenia or immune thrombocytopenia meets the applicable approved indication and platelet criteria.
    • Droxidopa: Symptomatic neurogenic orthostatic hypotension is documented, including an appropriate underlying autonomic disorder.
    • Erlotinib: Initial therapy requires an approved oncology indication and, when applicable, confirmation of an EGFR-sensitive mutation and appropriate disease setting.
    • Everolimus: Initial therapy requires a qualifying oncology, transplant, tuberous sclerosis complex, or other FDA-approved indication with supporting documentation.

    Dupixent Initial and Continuation Therapy

    Dupixent coverage requires the applicable initial or continuation criteria for the treated condition.

    Dupixent initial therapy

    • Atopic dermatitis: patient meets the applicable age requirement and has disease requiring systemic or otherwise appropriate therapy.
    • Asthma: patient meets the age requirement; blood eosinophils are at least 150 cells/microliter within the prior 6 weeks or the patient has oral-corticosteroid-dependent asthma; the patient has used an inhaled corticosteroid with at least one additional controller; and asthma was uncontrolled before monoclonal-antibody therapy, based on exacerbations, healthcare utilization, pulmonary function, or worsening during corticosteroid taper.
    • COPD: blood eosinophils are at least 300 cells/microliter within the prior 6 weeks or before monoclonal-antibody therapy; the patient received at least 3 months of combination therapy with at least two of LAMA, LABA, or ICS; and the patient had at least two exacerbations requiring systemic corticosteroids or antibiotics, or an exacerbation requiring hospitalization, during the prior 12 months.
    • CRSwNP: concurrent nasal corticosteroid use; at least two qualifying symptoms for 8 weeks; prior oral corticosteroid use or polyp surgery; and diagnosis confirmed by direct examination, endoscopy, or sinus CT.

    Epidiolex Through Fotivda Criteria

    These products require the disease-specific diagnosis, molecular or laboratory confirmation when applicable, and the listed prior-therapy requirements.

    Initial and continuation criteria

    • Epidiolex: Initial therapy requires an approved seizure-disorder indication, including Lennox-Gastaut syndrome, Dravet syndrome, or tuberous sclerosis complex, with appropriate age and diagnosis documentation. Continuation requires clinical benefit and tolerability.
    • Fasenra initial therapy—severe asthma: Severe eosinophilic asthma remains uncontrolled despite appropriate high-dose inhaled corticosteroid-based controller therapy and meets the applicable eosinophil and exacerbation criteria.
    • Fasenra initial therapy—EGPA: Eosinophilic granulomatosis with polyangiitis is documented and treatment is medically necessary for the approved indication.
    • Fasenra initial therapy—HES: Hypereosinophilic syndrome is documented and meets the approved disease criteria.

    Concurrent therapy with another monoclonal antibody is excluded when the product-specific policy prohibits combination use; examples include Adbry, Cinqair, Ebglyss, Fasenra, Nemluvio, Nucala, Tezspire, and Xolair. Concurrent use with oral or topical Janus kinase inhibitors is excluded when prohibited by the product criteria.

    Coverage is not provided for prophylactic use when the policy requires treatment of an active disease, for diagnoses lacking required laboratory, pathology, molecular, or imaging confirmation, or when required prerequisite therapy has not been completed. Products must not be duplicated across overlapping indications or presentations when concurrent use is restricted.

    Part B versus Part D determination is made at prior-authorization review when applicable. Claims for dialysis-related anemia should be submitted under the ESRD bundled payment benefit rather than Medicare Part D.

    Initial Therapy: ABRYSVO Through Genotropin and Genotropin MiniQuick

    Initial therapy requires the applicable diagnosis, age, specialist, laboratory, molecular, and prerequisite-therapy requirements.

    Initial therapy criteria

    • ABRYSVO through Genotropin: Initial coverage is allowed only for the documented FDA-approved or medically accepted indication, with the product-specific age, diagnostic confirmation, prescriber, laboratory, and prerequisite-therapy requirements satisfied.
    • ABRYSVO: Patient has not previously received an RSV vaccine and meets the applicable non-pregnant age/risk or pregnancy gestational-age requirement.
    • ANKTIVA: High-risk BCG-unresponsive non-muscle-invasive bladder cancer with carcinoma in situ, used with BCG; patient is at least 18 and treatment is prescribed by or in consultation with an oncologist or urologist.
    • Aldurazyme, alpha-1 proteinase inhibitor, Cerezyme, and Cystaran: Required enzyme, molecular, laboratory, or disease-specific diagnostic confirmation is present before treatment begins.

    Continuation and Maintenance Therapy

    Continuation or maintenance coverage requires ongoing eligibility, clinical benefit, and compliance with monitoring and prerequisite therapy.

    Continuation and maintenance therapy

    • The patient remains diagnosed with the covered condition, continues to meet age and specialist requirements, and has not developed an exclusion or contraindication.
    • Clinical response or ongoing medical necessity is documented. Depending on the product, response may include reduced symptoms, exacerbations, seizures, lesions, hives, disease activity, transfusion or steroid requirements, or improved function.
    • Required concomitant or prerequisite therapy is continued, including inhaled or intranasal corticosteroids, LABA/LAMA therapy, BCG, background lupus therapy, multidrug antimycobacterial therapy, or other product-specific therapy.
    • Required monitoring is completed, including laboratory, pulmonary, cardiac, ophthalmic, endocrine, REMS, or disease-specific safety monitoring as applicable.

    Prior Authorization and Submission Requirements

    Prior Authorization

    Initial Prior Authorization and Authorization Durations

    Prior authorization is required for ABRYSVO and the one-year specialty therapies identified below. Submit the diagnosis, relevant clinical documentation, and treatment history when specified; verify that duration and prerequisite requirements are met before requesting approval.

    • ABRYSVO: Coverage is 3 months. Patient must be non-pregnant and age 50 years or older, or age 18 through 49 years with increased risk for lower respiratory tract disease; pregnant patients must be 32 through 36 weeks' gestation.
    • ABRYSVO RSV-vaccination restriction: Confirm the patient has not already received an RSV vaccine.
    • AKEEGA: Coverage is 1 year. Submit diagnosis of metastatic castration-resistant or metastatic castration-sensitive prostate cancer, BRCA mutation documentation, and evidence of combination use with prednisone plus concurrent GnRH analog therapy or prior bilateral orchiectomy.
    • ALUNBRIG: Coverage is 1 year. Submit ALK status and document the applicable disease indication. For newly treated advanced or metastatic ALK-positive NSCLC, document a prior trial of Alecensa, Ensacove, or Lorbrena.
    • One-year specialty drug authorizations: The source criteria specify 1-year coverage for AKEEGA and ALUNBRIG; request the applicable authorization duration and include all required clinical information.

    Initial Therapy Decision Logic

    Initial therapy criteria: ABRYSVO through CABOMETYX

    Initial therapy is covered when the applicable product-specific pathway is satisfied.

    ABRYSVO through ALYFTREK: Meet the stated RSV eligibility and no prior vaccination; meet AKEEGA prostate cancer, ALDURAZYME diagnostic, ALECENSA disease-specific, alpha-1 proteinase inhibitor laboratory, ALUNBRIG ALK/prior-therapy, and ALYFTREK cystic-fibrosis criteria as applicable.
    ANKTIVA through AVMAPKI-FAKZYNJA: Meet the applicable bladder cancer, DIRA, MAC lung disease, ROS1/NTRK malignancy, or recurrent KRAS-mutated low-grade serous cancer criteria, including required age, combination, biomarker, and prior-treatment requirements.
    AYVAKIT: GIST with PDGFRA exon 18 mutation or two prior specified therapies; PDGFRA D842V myeloid/lymphoid neoplasm with eosinophilia; or eligible systemic mastocytosis with platelets at least 50,000/mcL.

    Continuation and Maintenance Therapy

    Continuation criteria: ANKTIVA through Cosentyx

    Continuation therapy is covered when the patient remains clinically appropriate for treatment and demonstrates the required response or treatment status.

    ANKTIVA: The covered indication remains active and maintenance therapy is prescribed by or in consultation with an oncologist or urologist.
    ARCALYST: Positive response to therapy is documented.
    ARIKAYCE: Continued background multidrug regimen and MAC culture criterion are present.
    BENLYSTA: Lupus nephritis: concurrent immunosuppression and response; SLE: concurrent standard therapy.

    Required Prerequisite and Sequencing Therapy

    ProductIndicationPrerequisite or sequencing requirement
    AlunbrigAdvanced or metastatic ALK-positive non-small cell lung cancerFor patients new to Alunbrig therapy, trial Alecensa, Ensacove, or Lorbrena before approval.
    ANKTIVAInitial treatment of high-risk BCG-unresponsive non-muscle-invasive bladder cancer with carcinoma in situUse in combination with BCG.
    ARCALYSTDeficiency of interleukin-1 receptor antagonistPrior subcutaneous anakinra therapy with clinical benefit.
    Atypical antipsychoticsApplicable covered indicationsTrial of two of olanzapine, quetiapine fumarate, risperidone, or ziprasidone. Paliperidone extended-release for schizoaffective disorder is exempt.
    AVMAPKI-FAKZYNJARecurrent low-grade serous ovarian, fallopian tube, or primary peritoneal cancerAt least one prior systemic therapy; examples include paclitaxel, carboplatin, bevacizumab, letrozole, anastrozole, or exemestane.
    AVMAPKI-FAKZYNJARecurrent low-grade serous cancer with a KRAS mutationPrior systemic therapy is required; at least one systemic therapy must have been tried.
    AYVAKITGastrointestinal stromal tumorTry two of imatinib, sunitinib, dasatinib, regorafenib, or ripretinib, unless the tumor has a PDGFRA exon 18 mutation.
    BALVERSAUrothelial carcinomaProgression during or following prior platinum-containing chemotherapy, other chemotherapy, or checkpoint inhibitor therapy.
    BosentanChronic thromboembolic pulmonary hypertensionTry Adempas, have a contraindication to Adempas, or be currently receiving bosentan for CTEPH.
    BRIUMVIRelapsing-remitting multiple sclerosisTried and failed two other multiple sclerosis therapies.
    CABOMETYXRET rearrangement-positive non-small cell lung cancerPrior targeted therapy with progression on Gavreto or Retevmo.
    CALQUENCEMantle cell lymphoma; marginal zone lymphoma; or Waldenstrom macroglobulinemia/lymphoplasmacytic lymphomaFor mantle cell lymphoma, try at least one systemic regimen or document inability to receive one, unless CALQUENCE is used with rituximab. The other listed lymphomas require prior systemic therapy.
    ProductIndicationPrerequisite or sequencing requirement
    CAMCEVIProstate cancerPrior trial of Orgovyx or Eligard.
    ClobazamLennox-Gastaut syndromeTried or currently receiving lamotrigine, topiramate, rufinamide, felbamate, Fintepla, Epidiolex, or valproic acid.
    ClobazamTreatment-refractory seizures or epilepsyTried or currently receiving at least two other antiepileptic drugs.
    CometriqRET-positive non-small cell lung cancerProgression on Gavreto or Retevmo.
    CometriqDifferentiated thyroid carcinomaPrior Lenvima or sorafenib after the disease is refractory to radioactive iodine.
    CopiktraChronic lymphocytic leukemia or small lymphocytic lymphomaBoth prerequisite categories are required: at least one Bruton tyrosine kinase inhibitor and at least one Venclexta-based regimen.
    CopiktraChronic lymphocytic leukemia or small lymphocytic lymphomaPrior treatment with at least one Bruton tyrosine kinase inhibitor and at least one Venclexta (venetoclax)-based regimen.
    Cortrophin GelFDA-approved diagnoses other than acute multiple sclerosis exacerbationTrial of a systemic corticosteroid for the current condition with severe adverse effects or treatment failure.
    CosentyxPlaque psoriasisTry at least one traditional systemic agent for at least 3 months unless intolerant, or document a contraindication to methotrexate. A biologic other than Cosentyx or a Cosentyx biosimilar also counts.
    CosentyxHidradenitis suppurativaTry at least one other therapy, such as systemic antibiotics or isotretinoin.
    DroxidopaSymptomatic neurogenic orthostatic hypotensionPrior trial of midodrine.
    DopteletInitial chronic or persistent immune thrombocytopeniaTry one other therapy, such as systemic corticosteroids, intravenous immunoglobulin, anti-D immunoglobulin, eltrombopag, romiplostim, fostamatinib, or rituximab, or undergo splenectomy.
    Diclofenac sodium topical productsFDA-approved indicationsPrerequisite therapy is required; the specific agent and failure criteria are not specified.
    DUAVEEMedically accepted indicationsPrerequisite therapy is required; the specific agent and failure criteria are not specified.
    EnbrelRheumatoid arthritis, juvenile idiopathic arthritis, juvenile rheumatoid arthritis, psoriatic arthritis, or plaque psoriasisGenerally try one preferred adalimumab product; a non-preferred adalimumab trial also counts. The requirement does not apply to patients younger than 18 years with plaque psoriasis or psoriatic arthritis.
    EnbrelBehcet diseasePrior conventional therapy, such as a systemic corticosteroid, immunosuppressant, interferon alfa, or mycophenolate, or prior adalimumab or infliximab.
    EmrelisEligible nonsquamous non-small cell lung cancerAt least one prior systemic therapy.
    ProductIndicationPrerequisite or sequencing requirement
    EnsacoveNew-start non-small cell lung cancerUse preferred Alecensa or Lorbrena first, unless the prescriber documents that a preferred product is inappropriate for the patient's specific clinical situation; Alunbrig is also referenced in the exception language.
    EpidiolexDravet syndromeTry or use concomitantly at least two other antiseizure drugs, or one of Diacomit, clobazam, or Fintepla.
    EpidiolexLennox-Gastaut syndrome, tuberous sclerosis complex, or refractory epilepsyTry or use concomitantly at least two other antiseizure drugs.
    ErivedgeMedulloblastomaTry at least one chemotherapy agent; the prescriber must identify a sonic hedgehog pathway mutation.
    ErlotinibChordomaAt least one previous therapy must have been tried.
    ErlotinibChordoma, renal cell carcinoma, or pancreatic cancerChordoma requires prior therapy; renal cell carcinoma requires combination therapy with bevacizumab; pancreatic cancer requires combination therapy with gemcitabine.
    EverolimusIndication-specific oncology usesDisease-specific prior treatment is required where specified, including prior endocrine therapy, systemic therapy, chemotherapy, or other disease-directed treatment; required combination therapy also applies for selected indications.
    FasenraAsthma or eosinophilic granulomatosis with polyangiitisAsthma: prior inhaled corticosteroid plus at least one additional controller or maintenance medication. EGPA: systemic corticosteroid therapy for at least 4 weeks.
    FinteplaDravet syndrome or Lennox-Gastaut syndromeTry or use concomitantly at least two other antiepileptic drugs. For Dravet syndrome, Epidiolex, clobazam, or Diacomit may alternatively satisfy the prerequisite.
    FotivdaRelapsed or stage IV renal cell carcinomaAt least two other systemic regimens must have been tried.
    FruzaqlaAdvanced or metastatic colon, rectal, or appendiceal cancerPrior fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy plus an anti-VEGF agent. For RAS wild-type disease, anti-EGFR therapy must be medically inappropriate or previously received.
    GilotrifMetastatic squamous NSCLC or non-nasopharyngeal head and neck cancerPrior platinum-based chemotherapy with disease progression after or during treatment.

    Clinical Thresholds and Measurement Requirements

    Laboratory and physiologic thresholds
    Alpha-1 proteinase inhibitorsBaseline alpha-1-antitrypsin serum concentration must be <80 mg/dL or <11 micromol/L.
    ARANESP—CKD anemiaInitial threshold: Hb <10.0 g/dL for adults or Hb ≤11.0 g/dL for children. After prior epoetin alfa, Mircera, or Aranesp: adults Hb ≤11.5 g/dL; children Hb ≤12.0 g/dL.
    ARANESP—chemotherapy-associated anemiaInitial Hb threshold is ≤10.0 g/dL; after prior epoetin alfa or Aranesp, Hb threshold is ≤12.0 g/dL.
    ARANESP—MDS anemiaInitial threshold: Hb ≤10.0 g/dL or serum erythropoietin ≤500 mU/mL.
    ARANESP—maximum hemoglobinDeny when Hb is >12.0 g/dL.
    AYVAKITPlatelet count must be ≥50,000/mcL for the systemic mastocytosis criterion.

    Authorization Durations and Quantity Parameters

    Quantity limits and authorization durations
    Doptelet—chronic liver diseaseAuthorization duration is 5 days per course.
    Doptelet—initial chronic/persistent ITPAuthorization duration is 14 weeks per course.
    DECNUPAZ, deferasirox, deferiprone, dimethyl fumarate, and droxidopaAuthorization duration is 12 months or 1 year.
    Eligard presentations and TriptodurAuthorization duration is 1 year for Eligard, Eligard 3 Month, Eligard 4 Month, Eligard 6 Month, and Triptodur.
    HaegardaAuthorization duration is 1 year.
    HernexeosAuthorization duration is 1 year.
    Glatiramer and Glatopa

    Administration and Site-of-Care Requirements

    Billing Rule

    Ensure ophthalmologist supervision for Eylea

    Arrange for Eylea to be administered by or under the supervision of an ophthalmologist. Prior authorization is required for FDA-approved indications, and the authorization may be issued for 3 years.

    • Administration setting: office.
    • Submit the diagnosis with the prior authorization request.

    Clinical and Policy Definitions

    Definitions
    GnRH analogExamples include leuprolide acetate, Lupron Depot, Trelstar, Zoladex, Vantas, Firmagon, and Orgovyx.
    Clinical presentation consistent with cystic fibrosisExamples include meconium ileus, sinopulmonary symptoms, bronchiectasis, sinusitis, failure to thrive, and pancreatic insufficiency.
    PAH WHO Group 1Pulmonary arterial hypertension classified as WHO Group 1 and confirmed by right-heart catheterization.
    High-risk BCG-unresponsive non-muscle-invasive bladder cancerBladder cancer that has not invaded the bladder muscle and is high-risk and unresponsive to BCG treatment; carcinoma in situ is required under the stated initial criteria.
    Anemia with chronic renal failure and MAC lung diseaseAnemia associated with chronic renal failure. MAC lung disease is Mycobacterium avium complex lung disease requiring a multidrug background regimen.
    NTRK fusion, tardive dyskinesia, and Huntington disease chorea

    Policy Background

    ABRYSVO (PF) is an RSV vaccine covered under the HealthSpring Medicare Part D benefit when the applicable FDA-approved eligibility pathway is met. For non-pregnant individuals, coverage applies at 50 years of age or older, or for adults aged 18 through 49 years who are at increased risk for lower respiratory tract disease. For pregnant individuals, eligibility is limited to 32 through 36 weeks of gestation.

    The patient must not have already received an RSV vaccine. Prior authorization is required, and the standard authorization duration is 3 months.

    Biosimilar and Preferred-Product Considerations

    Step Therapy

    Document qualifying non-Cosentyx biologic history

    For plaque psoriasis requests, document a trial of at least one biologic that is not Cosentyx or a Cosentyx biosimilar when using biologic treatment history to satisfy the systemic-therapy prerequisite. A traditional systemic agent trial of at least 3 months also qualifies unless the patient was intolerant, or a methotrexate contraindication may be documented.

    • Concurrent use with another biologic or targeted synthetic DMARD is excluded.
    • Continuation requires that the patient has experienced benefit from Cosentyx.
    Policy Summary
    PayerHealthSpring
    PolicyABRYSVO RSV Vaccine Prior Authorization Criteria
    Policy CodePolicy N/A
    Change TypeNo material clinical or coverage changes
    Effective DateN/A
    Last ReviewNov 1, 2026
    Next Review DateN/A
    Key ActionSubmit a prior authorization request establishing that the patient meets the applicable age, risk, or gestational-age criteria and has not already received an RSV vaccine.
    SourceLink
    On This Page
    Covered Products and Clinical CriteriaPrior Authorization and Submission RequirementsInitial Therapy Decision LogicContinuation and Maintenance TherapyRequired Prerequisite and Sequencing TherapyClinical Thresholds and Measurement RequirementsAuthorization Durations and Quantity ParametersAdministration and Site-of-Care RequirementsClinical and Policy DefinitionsPolicy BackgroundBiosimilar and Preferred-Product Considerations
    Cometriq: Appropriate advanced or metastatic oncology indication is documented and therapy is prescribed by or in consultation with an oncology specialist.
  1. Copaxone: Relapsing multiple sclerosis or another covered multiple-sclerosis indication is documented.
  2. Copiktra: Hematologic malignancy meeting the approved indication is documented, including the applicable chronic lymphocytic leukemia, small lymphocytic lymphoma, or follicular lymphoma criteria. Coverage requires the applicable prior therapy and disease status.
  3. Cortrophin Gel: A covered inflammatory or autoimmune indication is documented, with appropriate specialist evaluation and medical necessity.
  4. Cosentyx: Initial therapy requires a covered inflammatory disease indication and applicable prior treatment; continuation requires clinical response or ongoing medical necessity.
  5. Cotellic: Appropriate oncology indication, including qualifying BRAF V600E or V600K mutation-positive melanoma when used with vemurafenib, is documented.
  6. Cystaran: Cystinosis with corneal cystine crystal deposition is documented.
  7. Dalfampridine: Multiple sclerosis-related walking impairment is documented; continuation requires demonstrated functional benefit.
  8. Deferasirox: Chronic iron overload requiring chelation is documented; initial and continuation therapy require appropriate laboratory monitoring and response or ongoing need.
  9. Fruzaqla: Advanced or metastatic colorectal cancer is documented after the required prior systemic therapies, including fluoropyrimidine-, oxaliplatin-, and irinotecan-based therapy and, when applicable, biologic therapy.
  10. Gattex: Short bowel syndrome with dependence on parenteral support is documented; initial therapy requires appropriate intestinal rehabilitation and monitoring.
  11. Gavreto: RET fusion-positive solid tumor or RET-mutated medullary thyroid cancer meeting the approved indication is documented.
  12. Gefitinib: EGFR-mutated non-small cell lung cancer is confirmed by an FDA-approved or validated molecular test.
  13. Gilenya: Continuation requires ongoing treatment for multiple sclerosis, clinical benefit, and required safety monitoring.
  14. Gilotrif: Initial therapy requires metastatic non-small cell lung cancer with an FDA-approved EGFR mutation and appropriate treatment setting.
  15. Glatiramer: Relapsing multiple sclerosis or another covered multiple-sclerosis indication is documented.
  16. Eligard, Eligard presentations, and Triptodur: Appropriate hormone-sensitive prostate cancer or central precocious puberty indication is documented, with the product presentation selected for the patient's treatment schedule.
  17. Growth hormone deficiency: Growth hormone deficiency is confirmed through appropriate endocrine evaluation and testing, and treatment meets age, diagnosis, and specialist requirements.
  18. Other indication-based products: Coverage requires a documented FDA-approved or medically accepted indication, supporting diagnosis, and any applicable specialist or prerequisite-therapy requirements.
  19. Eosinophilic esophagitis: weight at least 15 kg, biopsy showing at least 15 intraepithelial eosinophils per high-power field, no secondary cause, and an 8-week trial of prescription-strength PPI.
  20. Prurigo nodularis: pruritus has lasted at least 6 weeks. Chronic spontaneous urticaria: urticaria has lasted more than 6 weeks despite nonsedating H1-antihistamine treatment. Allergic fungal rhinosinusitis: IgE-mediated response to fungal hyphae is confirmed and nasal polyps are present.
  21. Prescriber requirements apply by indication: allergist, immunologist, dermatologist, pulmonologist, otolaryngologist, rhinologist, gastroenterologist, infectious-disease specialist, or other applicable specialist.
  22. Dupixent continuation therapy

    • Atopic dermatitis: continued medical necessity is documented.
    • Asthma: patient is responding positively to therapy and continues inhaled corticosteroid therapy.
    • COPD: patient has received Dupixent for at least 6 months, continues LABA and LAMA therapy, and demonstrates benefit such as reduced symptoms, exacerbations, hospitalizations, emergency visits, or improved lung function.
    • CRSwNP: patient has received Dupixent for at least 6 months, is responding positively, and continues intranasal corticosteroid therapy.
    • Eosinophilic esophagitis: patient has received therapy for at least 6 months and has reduced eosinophil counts, dysphagia or swallowing pain, or food impactions.
    • Prurigo nodularis, chronic spontaneous urticaria, bullous pemphigoid, and allergic fungal rhinosinusitis: patient has received at least 6 months of therapy and demonstrates the applicable clinical response, such as reduced lesions, pruritus, hives, skin involvement, nasal polyps, congestion, sinonasal symptoms, or corticosteroid use.
    Fasenra continuation therapy: Patient demonstrates clinical benefit, including reduced exacerbations, symptoms, steroid requirement, or disease activity, and continues appropriate monitoring.
  23. Fintepla initial therapy: Dravet syndrome or Lennox-Gastaut syndrome is documented for the applicable age group and treatment setting.
  24. Fintepla continuation therapy: Patient demonstrates reduction in seizure frequency or other clinically meaningful benefit and remains compliant with required monitoring.
  25. Fotivda: Initial therapy is for adults with relapsed or stage IV renal cell carcinoma after at least two systemic regimens; examples include axitinib, cabozantinib, sunitinib, or pazopanib-based regimens.
  26. Akeega, Alecensa, Alunbrig, Ayvakit, Balversa, Cometriq, Copiktra, Cotellic, Erlotinib, Everolimus, Fotivda, Fruzaqla, Gavreto, Gefitinib, Gilotrif, and other oncology products: The qualifying tumor type, biomarker or molecular alteration when required, disease stage, and prior-therapy requirements are documented.
  27. ARANESP: Initial hemoglobin, erythropoietin, chemotherapy, CKD, MDS, and age requirements are met; dialysis-related anemia is excluded from Part D coverage.
  28. Dupixent, Fasenra, Epidiolex, Fintepla, Cosentyx, Dalfampridine, Deferasirox, Doptelet, Droxidopa, and other products: The applicable initial disease-specific criteria and prerequisite therapy are satisfied.
  29. Genotropin and Genotropin MiniQuick: Growth hormone deficiency or another covered indication is confirmed by appropriate endocrine evaluation; other Genotropin indications require documentation of the applicable FDA-approved or medically accepted use.
  30. BENLYSTA, ARCALYST, CAMZYOS, Clobazam, Cosentyx, Dalfampridine, Deferasirox, Dupixent, Epidiolex, Fasenra, Fintepla, and Gilenya: Continuation requires documented benefit or stable ongoing need and adherence to the applicable monitoring and duration rules.
  31. Growth hormone products: Continuation requires persistent deficiency or another covered indication, objective benefit or continued medical necessity, appropriate growth or endocrine monitoring, and no indication that treatment should be discontinued.
  32. Prior Authorization

    AVMAPKI-FAKZYNJA Prior Authorization

    AVMAPKI-FAKZYNJA requires prior authorization and is approved for a limited ovarian, fallopian-tube, or primary-peritoneal cancer population when the required diagnosis, KRAS mutation, and prior systemic therapy are documented.

    • Submit diagnosis of recurrent low-grade serous ovarian, fallopian tube, or primary peritoneal cancer.
    • Document a KRAS mutation.
    • Document failure or use of at least one systemic therapy, such as paclitaxel, carboplatin, bevacizumab, letrozole, anastrozole, or exemestane.
    • Coverage duration is 1 year; the patient must be 18 years or older.
    • The request may include medically accepted fallopian-tube or primary-peritoneal cancer use when the listed criteria are satisfied.
    Prior Authorization

    CEREZYME Prior Authorization

    CEREZYME requires prior authorization, specialist involvement, and diagnostic confirmation of Gaucher disease. Submit genetic and laboratory documentation and confirm that no other approved Gaucher disease therapy will be used concurrently.

    • Coverage duration is 1 year.
    • Prescriber must be, or consult with, a geneticist, endocrinologist, metabolic-disorder subspecialist, or physician specializing in lysosomal storage disorders.
    • Submit diagnosis plus genetic testing and laboratory results.
    • For type 1 Gaucher disease, document deficient beta-glucocerebrosidase activity in leukocytes or fibroblasts, or biallelic pathogenic GBA variants on molecular genetic testing.
    • For type 3 Gaucher disease, document the same diagnostic confirmation and confirm the drug is not being used to manage neurologic manifestations.
    • Do not request concurrent use with Cerdelga, Elelyso, VPRIV, or Zavesca.
    Prior Authorization

    Droxidopa Prior Authorization

    Droxidopa requires prior authorization for adults with symptomatic neurogenic orthostatic hypotension and requires cardiology or neurology prescribing or consultation.

    • Coverage duration is 12 months.
    • Patient must be 18 years or older.
    • Document symptomatic neurogenic orthostatic hypotension caused by primary autonomic failure, Parkinson's disease, multiple system atrophy, pure autonomic failure, dopamine beta-hydroxylase deficiency, or non-diabetic autonomic neuropathy.
    • Document a prior trial of midodrine.
    • Submit medication history describing the required prior therapy.
    Prior Authorization

    FOTIVDA Prior Authorization

    FOTIVDA requires prior authorization for relapsed or stage IV renal cell carcinoma after at least two systemic regimens. Submit the diagnosis and treatment history; approved authorization is for 1 year.

    • Patient must be 18 years or older.
    • Submit documentation of relapsed or stage IV renal cell carcinoma.
    • Document trials of at least two systemic regimens, such as axitinib, axitinib plus pembrolizumab, cabozantinib, cabozantinib plus nivolumab, sunitinib, or pazopanib.
    • Include other therapies and treatment history with the request.
    • Coverage duration is 1 year.
    Step Therapy

    Required Prior Therapy, Preferred Products, and Specialists

    Meet all applicable prerequisite and preferred-product requirements before submission. Requests may be denied when required prior therapy, sequencing, or specialist involvement is absent.

    • ALUNBRIG: For patients new to therapy with advanced or metastatic ALK-positive NSCLC, document a trial of Alecensa, Ensacove, or Lorbrena before requesting approval.
    • AKEEGA: Document required combination therapy with prednisone and either concurrent GnRH analog treatment or prior bilateral orchiectomy.
    • AVMAPKI-FAKZYNJA: Document at least one prior systemic therapy.
    • Droxidopa: Document a prior midodrine trial and cardiology or neurology prescriber involvement.
    • FOTIVDA: Document at least two prior systemic regimens for relapsed or stage IV RCC.
    • CEREZYME: Specialist authorization is required; do not combine with another approved Gaucher disease therapy.
    Documentation Required

    Required Medical Documentation

    Submit complete medical information supporting the requested indication. Missing diagnosis, laboratory, biomarker, treatment-history, or specialist documentation can delay review or result in denial.

    • ABRYSVO: age, pregnancy status when applicable, increased-risk status for adults age 18 through 49, and confirmation of no prior RSV vaccination.
    • AKEEGA: prostate cancer diagnosis, BRCA mutation, prednisone combination, and GnRH analog or orchiectomy status.
    • ALUNBRIG: ALK rearrangement/fusion or ALK-positive disease documentation and the applicable disease characteristics.
    • AVMAPKI-FAKZYNJA: recurrent low-grade serous cancer diagnosis, KRAS mutation, and prior systemic therapy.
    • CEREZYME: Gaucher disease diagnosis, beta-glucocerebrosidase laboratory activity or biallelic GBA variant results, and specialist information.
    • Droxidopa: symptomatic neurogenic orthostatic hypotension diagnosis, etiology, medication history, and midodrine trial.
    • FOTIVDA: relapsed or stage IV RCC diagnosis and documentation of at least two prior systemic regimens.
    Denial Risk

    Denial Risks and Exclusions

    Review the request for exclusion criteria, concurrent therapy restrictions, and unmet clinical requirements before submission. The following issues may result in denial.

    • Prior RSV vaccination or failure to meet ABRYSVO age, risk, or pregnancy-window criteria.
    • AKEEGA request without BRCA-mutated metastatic castration-resistant or metastatic castration-sensitive prostate cancer, prednisone combination, and required androgen-deprivation status.
    • ALUNBRIG request without documented ALK-positive disease or without the required prior ALK-inhibitor trial for newly treated advanced or metastatic NSCLC.
    • AVMAPKI-FAKZYNJA request without recurrent low-grade serous disease, KRAS mutation, or prior systemic therapy.
    • CEREZYME request without diagnostic confirmation, required specialist involvement, or with concomitant Gaucher disease therapy.
    • Droxidopa request without symptomatic neurogenic orthostatic hypotension, qualifying etiology, or prior midodrine trial.
    • FOTIVDA request without relapsed or stage IV RCC or without at least two prior systemic regimens.
    • Missing required medical information, diagnosis, laboratory results, biomarker results, or treatment history.
    Note

    Indication and Benefit Verification

    Confirm the request is submitted for an FDA-approved or specified medically accepted indication and that the requested product, dose, and duration match the applicable criteria. Part B prerequisites are not required for the therapies described in these source criteria.

    • ABRYSVO: all FDA-approved indications; Part B prerequisite not required.
    • AKEEGA: all FDA-approved indications; Part B prerequisite not required.
    • ALUNBRIG: all FDA-approved and specified medically accepted indications, including Erdheim-Chester disease, inflammatory myofibroblastic tumor, peripheral T-cell lymphoma, and ALK-positive NSCLC; Part B prerequisite not required.
    • AVMAPKI-FAKZYNJA: all FDA-approved and specified medically accepted indications; Part B prerequisite not required.
    • CEREZYME: all FDA-approved indications; Part B prerequisite not required.
    • Droxidopa: all FDA-approved indications; Part B prerequisite not required.
    • FOTIVDA: all FDA-approved indications; Part B prerequisite not required.
    BALVERSA:
    FGFR-altered urothelial carcinoma with prior progression, qualifying FGFR-altered pancreatic adenocarcinoma, or metastatic FGFR-altered NSCLC.
    BENLYSTA: Biopsy-confirmed lupus nephritis with immunosuppression, or autoantibody-positive SLE with standard therapy unless significant toxicity prevents tolerance.
    Bosentan: WHO Group 1 PAH confirmed by right-heart catheterization, or CTEPH with Adempas trial, contraindication, or ongoing bosentan.
    BRAFTOVI: BRAF V600/V600E-positive malignancy with the applicable disease-stage and combination or prior-treatment requirement.
    BRUKINSA: Eligible lymphoma or leukemia diagnosis with the applicable prior systemic therapy, disease status, and combination-treatment requirement.
    CABOMETYX: Eligible malignancy with the applicable disease stage, histology, biomarker, prior-treatment, or combination-treatment requirement.

    Initial therapy criteria: CAMZYOS through Epoetin alfa

    Initial therapy is covered when the requested indication and all applicable clinical requirements are met.

    CAMZYOS: Obstructive HCM with associated symptom, NYHA Class II or III symptoms, qualifying LV hypertrophy, and peak LVOT gradient at least 50 mmHg.LV wall thickness >=15 mm, or >=13 mm with familial HCM; LVOT gradient >=50 mmHg
    Clobazam: Lennox-Gastaut syndrome with a qualifying antiseizure regimen, or treatment-refractory seizures/epilepsy with at least two other antiepileptic drugs; age at least 2 years and neurologist involvement are required.
    Cometriq: Medullary thyroid carcinoma; RET-positive advanced/recurrent/metastatic NSCLC after Gavreto or Retevmo; or radioactive-iodine-refractory differentiated thyroid carcinoma after Lenvima or sorafenib.
    Copiktra: CLL/SLL after a BTK inhibitor and Venclexta-based regimen; peripheral T-cell lymphoma; or specified relapsed/refractory T-cell lymphoma.
    Cosentyx: Hidradenitis suppurativa after prior therapy; non-radiographic axial spondyloarthritis with objective inflammation; or plaque psoriasis after systemic therapy or with methotrexate contraindication.
    Dalfampridine: Ambulatory adult with MS-related impaired ambulation documented by an objective measure.
    Deferasirox: Regular transfusions with ferritin above 1,000 mcg/L, or non-transfusion-dependent thalassemia with ferritin above 300 mcg/L.
    Deferiprone: Chronic transfusion-related iron overload due to thalassemia syndrome, sickle cell disease, or another anemia.
    Doptelet: Chronic liver disease thrombocytopenia with platelets below 50 x 10^9/L and scheduled procedure, or ITP meeting platelet/bleeding-risk criteria plus prior therapy or splenectomy.
    Droxidopa: Symptomatic neurogenic orthostatic hypotension due to an eligible autonomic condition and prior midodrine trial.
    Dupixent: Meet the indication-specific age, disease, laboratory, prior-treatment, and specialist criteria for the requested indication.
    Elaprase: Diagnostic laboratory or molecular confirmation of deficient iduronate-2-sulfatase activity.
    Emrelis: Locally advanced or metastatic nonsquamous NSCLC, high c-Met expression, and at least one prior systemic therapy.
    Enbrel: Meet the indication-specific age, specialist, and prerequisite-treatment criteria.
    Endari: Sickle cell disease, age at least 5 years, and qualified sickle-cell specialist involvement.
    Epidiolex: Qualifying seizure disorder with the specified prior or concomitant antiseizure therapy; initial therapy requires neurologist involvement.
    Epoetin alfa: Qualifying CKD, chemotherapy-associated, HIV/zidovudine, surgical, MDS, myelofibrosis, or dialysis anemia meeting the applicable laboratory and clinical criteria.

    Initial therapy criteria: Fasenra through Genotropin and Genotropin MiniQuick

    Initial therapy is covered when the applicable diagnosis-specific criteria are met.

    Fasenra asthma: Eosinophils at least 150 cells/microliter, prior ICS plus an additional controller, and uncontrolled asthma demonstrated by qualifying exacerbation, lung-function, or steroid-taper findings.
    Fasenra EGPA: Active non-severe EGPA, systemic corticosteroids for at least 4 weeks, and eosinophils at least 150 cells/microliter.
    Fasenra HES: FIP1L1-PDGFR-alpha-negative HES without an identifiable non-hematologic secondary cause; the source also requires the remaining stated HES criteria.
    Fintepla: Dravet syndrome with qualifying antiseizure therapy, or Lennox-Gastaut syndrome with at least two other antiepileptic drugs; age at least 2 years and neurologist involvement are required.
    Fotivda: Relapsed or stage IV renal cell carcinoma with at least two prior systemic regimens.
    Fruzaqla: Advanced or metastatic colorectal or appendiceal cancer with applicable biomarker/checkpoint criteria and prior fluoropyrimidine-, oxaliplatin-, irinotecan-, and anti-VEGF therapy; the RAS wild-type anti-EGFR condition also applies.
    Gattex: Parenteral nutrition on at least 3 days per week or inability to receive adequate total parenteral nutrition for caloric needs.
    Gavreto: Qualifying RET-positive NSCLC or thyroid cancer with the applicable disease extent, RET alteration, systemic-treatment, or radioactive-iodine-refractory criteria.
    Gefitinib: Advanced or metastatic NSCLC with sensitizing EGFR mutation-positive disease detected by an approved test.
    Gilotrif: Sensitizing EGFR-positive NSCLC, metastatic squamous NSCLC after platinum chemotherapy, or non-nasopharyngeal head and neck cancer after platinum chemotherapy.
    Gilenya: Relapsing multiple sclerosis, age at least 10 years, and neurologist or MS specialist involvement.
    Glatiramer/Glatopa: Relapsing multiple sclerosis with neurologist or MS specialist involvement; no concurrent MS disease-modifying agent.
    Haegarda: Type I or II HAE with low functional C1-inhibitor and C4, or type III HAE.
    Genotropin/Genotropin MiniQuick: Meet the applicable initial criteria for growth hormone deficiency, idiopathic short stature, CKD, Noonan, Prader-Willi, SHOX deficiency, SGA, Turner syndrome, or short bowel syndrome.
    Bexarotene: Diagnosis remains documented and oncologist or dermatologist involvement continues.
    CAMZYOS: At least 8 months established therapy, current or prior symptom, LVEF at least 50%, and objective benefit or symptom stabilization/improvement.LVEF >=50%
    Clobazam: Prescriber confirms response.
    Cosentyx: Benefit from treatment is documented.

    Continuation criteria: Dalfampridine through Haegarda

    Continuation therapy is covered when ongoing benefit, response, or established treatment is documented.

    Dalfampridine: The patient remains ambulatory, treatment continues for MS-related mobility, and response or benefit is documented.
    Deferasirox and deferiprone: The prescribing physician confirms the patient is benefiting from therapy.
    Doptelet: Beneficial response and continued bleeding risk are documented.
    Dupixent: The applicable duration, generally at least 6 months, and indication-specific clinical response are documented; asthma requires ICS and COPD requires LABA/LAMA.Generally at least 6 months
    Enbrel: The prescriber confirms response.
    Epidiolex: The patient is responding to therapy.
    Epoetin alfa: The patient is currently receiving an ESA and meets the applicable continuation laboratory criteria, generally including Hb at or below 12 g/dL.Hb <=12 g/dL
    Fasenra and Fintepla: The patient has responded to therapy; Fasenra response may include fewer flares, improved fatigue, reduced corticosteroid use, or decreased eosinophils.
    Gilenya: The patient has relapsing MS and is established on Gilenya.
    Genotropin: The prescriber confirms response for the specified growth indications, or short bowel syndrome treatment has been started or previously produced response.
    Haegarda: The patient has type I, II, or III HAE and favorable clinical response compared with baseline.
    CAMZYOS, carglumic acid, and ChemetCAMZYOS initial therapy: maximal LV wall thickness ≥15 mm, or ≥13 mm with familial hypertrophic cardiomyopathy, and peak LV outflow tract gradient ≥50 mmHg. CAMZYOS continuation: LVEF ≥50%. Carglumic acid acute PA or MMA treatment: plasma ammonia ≥50 micromol/L. Chemet: pretreatment blood lead level >45 mcg/dL.
    Treatment, laboratory, and diagnostic thresholds
    Cosentyx plaque psoriasisAt least 3 months of traditional systemic therapy, unless intolerant; a qualifying biologic trial or contraindication to methotrexate may also satisfy the criterion.
    Deferasirox—transfusion-related iron overloadPretreatment serum ferritin must be >1,000 mcg/L, with regular blood transfusions.
    Deferasirox—non-transfusion-dependent thalassemiaPretreatment serum ferritin must be >300 mcg/L.
    Doptelet—chronic liver diseaseCurrent platelet count must be <50 x 10^9/L; a procedure must be scheduled within 10 to 13 days after starting therapy.
    Doptelet—chronic/persistent ITPPlatelet count must be <30,000/mcL, or <50,000/mcL with increased bleeding risk; initial therapy also requires another therapy trial or prior splenectomy.
    Dupixent asthma and COPDAsthma blood eosinophils must be ≥150 cells/microliter; COPD blood eosinophils must be ≥300 cells/microliter, measured within the specified prior-treatment timeframe.
    Pulmonary function, eosinophilic esophagitis, and EmrelisAsthma FEV1: <80% predicted, or <90% for patients younger than 18 years; FEV1/FVC: <0.8, or <0.9 for patients younger than 18 years. Eosinophilic esophagitis: biopsy ≥15 intraepithelial eosinophils per high-power field and weight ≥15 kg. Emrelis: ≥50% of tumor cells with strong [3+] c-Met staining.
    Anemia, eosinophil, pulmonary-function, and growth-hormone thresholds
    Epoetin alfa—CKD anemiaInitial Hb threshold: <10.0 g/dL for adults or ≤11 g/dL for children. Continuation while receiving an ESA: Hb ≤12 g/dL.
    Epoetin alfa—chemotherapy-associated anemiaInitial Hb <10.0 g/dL, or Hb ≤12.0 g/dL while currently receiving an ESA.
    Epoetin alfa—HIV with zidovudine, MDS, and myelofibrosisInitial Hb <10.0 g/dL or serum erythropoietin ≤500 mU/mL; continuation while receiving an ESA requires Hb ≤12.0 g/dL.
    Epoetin alfa—surgical patientsHb must be ≤13 g/dL.
    Fasenra eosinophil thresholdsAsthma: blood eosinophils ≥150 cells/microliter within the previous 6 weeks or before another monoclonal antibody. EGPA: ≥150 cells/microliter within the previous 4 weeks or before a monoclonal antibody that may alter eosinophil levels.
    Fasenra asthma lung functionFEV1 <80% predicted, or <90% predicted for patients younger than 18 years, or FEV1/FVC <0.80.
    Growth hormone indicationsChildren/adolescents: two stimulation tests with peak GH <10 ng/mL, or one test <10 ng/mL plus a GHD risk factor. Adults/adolescents: insulin peak ≤5 mcg/L, arginine peak ≤6.5 mcg/L, or Macrilen peak ≤2.8 ng/mL with BMI ≤40; glucagon thresholds vary by BMI. Idiopathic short stature: baseline height <1.2 percentile or SDS <-2.25 and growth rate <4 cm/year or below the 10th percentile. CKD: height <5th percentile and height velocity below the 25th percentile. Turner syndrome: height <5th percentile; SHOX deficiency: <3rd percentile; Noonan syndrome and SGA: <5th percentile.
    Authorization duration is 1 year.
    NTRK is a neurotrophic receptor tyrosine kinase gene fusion. TD means tardive dyskinesia. Huntington disease chorea means chorea associated with Huntington disease.
    Relapsing multiple sclerosis, GIST, and RET-rearranged NSCLCRelapsing MS includes clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. GIST means gastrointestinal stromal tumor. RET rearrangement-positive NSCLC is non-small cell lung cancer with a rearranged RET gene.
    Definitions
    Relapsing MS and GISTRelapsing forms of MS include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. GIST means gastrointestinal stromal tumor.
    RET rearrangement-positive NSCLCNon-small cell lung cancer with a rearranged RET gene.
    NYHA functional classNYHA Class II indicates mild symptoms with moderate physical activity and some exercise limitation. Class III indicates noticeable symptoms with minimal physical activity and comfort only at rest.
    N-acetylglutamate synthase deficiencyA metabolic disorder associated with hyperammonemia.
    Gaucher disease types 1 and 3Type 1 is non-neuronopathic Gaucher disease. Type 3 is chronic neuronopathic Gaucher disease; treatment must not be used to manage neurological manifestations.
    Differentiated thyroid carcinoma and objective inflammationDifferentiated thyroid carcinoma includes papillary, follicular, and oncocytic carcinoma. Objective inflammation for non-radiographic axial spondyloarthritis is an elevated C-reactive protein beyond the upper limit of normal or sacroiliitis on MRI.
    BRAF V600 disease, NOH, and c-Met overexpressionBRAF V600 mutation-positive disease is required for specified Cotellic uses. NOH is neurogenic orthostatic hypotension associated with primary autonomic failure, dopamine beta-hydroxylase deficiency, or non-diabetic autonomic neuropathy. High c-Met overexpression means at least 50% of tumor cells show strong [3+] staining on an approved test.
    Definitions
    Eosinophilic esophagitis and ESAEosinophilic esophagitis requires endoscopic biopsy showing at least 15 intraepithelial eosinophils per high-power field and exclusion of a secondary cause. ESA means an erythropoiesis-stimulating agent.
    GnRH analogGonadotropin-releasing hormone analog therapy used as androgen-deprivation treatment in the Erleada criteria.
    EGFR mutation-positive NSCLCNon-small cell lung cancer with an EGFR mutation confirmed by an approved test; examples include exon 19 deletions, exon 21 L858R, L861Q, G719X, and S768I.
    Mismatch repair and microsatellite statuspMMR/MSS means proficient mismatch repair/microsatellite-stable disease. dMMR/MSI-H means deficient mismatch repair/microsatellite instability-high disease.
    RAS wild-type and RET-positive diseaseRAS wild-type means KRAS- and NRAS-mutation-negative disease. RET-positive disease means qualifying RET fusion-positive or RET-mutation-positive disease, depending on tumor type.
    Sensitizing EGFR mutationListed sensitizing mutations include exon 19 deletions, exon 21 L858R substitutions, L861Q, G719X, and S768I.
    Hereditary angioedema and HER2/ERBB2 mutationHereditary angioedema due to C1-inhibitor deficiency may be type I, II, or III; type I and II criteria reference functional C1-inhibitor and serum C4 levels. HER2/ERBB2 activating mutation means an activating mutation in human epidermal growth factor receptor 2 in NSCLC.